NIAID CLINICAL PRODUCTS CENTER (CPC)
ID: RFP-NIAID-75N93024R00018Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/opp/c418c9f44b534339939d87e2d6098a32/view
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.

    Point(s) of Contact
    Deborah Blyveis
    (240) 669-5143
    blyveisd@niaid.nih.gov
    Emily Bannister
    emily.bannister@nih.gov
    Files
    Title
    Posted
    RFP-NIAID-75N93024R00018 Final.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID) has issued a Request for Proposal (RFP-NIAID-75N93024R00018) seeking support for pharmacy and pharmaceutical oversight in clinical trials, both national and international. Proposals are due by January 17, 2025, and must be submitted electronically to designated locations. The contract, effective from April 1, 2026, to March 31, 2027, may include options for extending performance through 2033. Offerors must comply with specific reporting requirements, including Technical Progress Reports and adherence to Section 508 of the Rehabilitation Act for accessibility. The contract emphasizes the importance of managing financial conflicts of interest as mandated by federal regulations, ensuring transparency when disclosing potential conflicts. Key personnel in the contract must be specified, with restrictions on diverting their duties without prior approval. Additionally, contractors are obligated to acknowledge federal funding in publicity materials and adhere to various special requirements, including ensuring compliance with NIH’s policies on enhancing reproducibility and public access to research findings. The document outlines comprehensive contractual obligations, emphasizing accountability, transparency, and compliance with federal policies, reinforcing NIAID's commitment to rigorous public health research standards.
    Lifecycle
    Title
    Type
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Currently viewing
    Solicitation
    Similar Opportunities
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug products. The objective of this procurement is to secure high-quality formulated drug products to support preclinical, IND-enabling, and clinical studies, ensuring compliance with current Good Manufacturing Practices (cGMP). This initiative is critical for advancing therapeutic development and enhancing the drug development pipeline, which is vital for public health. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can reach out to Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases and enhancing biodefense capabilities. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 are due by January 21, 2025. Interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.
    In Vitro Assessments of Antimicrobial Activity
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity program to support in vitro testing for evaluating the therapeutic potential of compounds against infectious diseases. This initiative aims to enhance the understanding and treatment of infectious diseases by providing efficient assessment tools integrated into the product development pipeline, focusing on various pathogens including bacteria, fungi, viruses, and challenging pathogens that require innovative culturing techniques. The RFP will be available online around December 30, 2024, and proposals must be submitted via the NIAID electronic Contract Proposal Submission (eCPS) platform; interested parties can contact Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    NIAID Virology Quality Assurance
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a comprehensive quality assurance program for virologic assays related to HIV and other viral pathogens. The objective is to ensure the validity and comparability of laboratory data through proficiency testing panels and real-time assay controls, which are critical for ongoing and future studies on infectious diseases. This program has been operational since 1988 and supports approximately 110 laboratories globally, emphasizing the importance of maintaining high standards in virologic testing. Proposals are expected to be submitted electronically via the NIAID electronic Contract Proposal Submission (eCPS) website, with the solicitation anticipated to be available on or about January 9, 2025. For further inquiries, interested parties can contact Shawnice Williams at shawnice.williams@nih.gov or Ashley Kinderdine at ashley.kinderdine@nih.gov.
    NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Cancer Institute (NCI), has issued a Special Notice regarding a subcontract opportunity at the Frederick National Laboratory for Cancer Research (FNLCR) aimed at enhancing laboratory practices to meet Good Clinical Laboratory Practice (GCLP) standards. The primary objective is to engage a subcontractor to evaluate current laboratory operations, identify compliance gaps, and implement improvements related to sample management, data integrity, and overall laboratory quality standards. This initiative is crucial for ensuring the integrity of testing and data management, which will facilitate the approval of new vaccine recommendations and enhance the laboratory's quality management system. Interested parties should note that this notice is for informational purposes only, with responses treated as government property, and are encouraged to monitor SAM.gov for updates. The deadline for submissions is January 3, 2025, at noon EST, and inquiries can be directed to Jennifer Gnuschke at jennifer.gnuschke@nih.gov.
    Pathology Support for the National Institute of Environmental Health Sciences
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for pathology support services for the National Institute of Environmental Health Sciences (NIEHS) under solicitation number 75N96025R00003. The procurement aims to secure comprehensive pathology-related services, including technical support, histopathological evaluations, and assistance with reporting and publication of findings, with a contract period anticipated from July 2025 to July 2026, and options for extensions up to July 2035. This initiative is crucial for enhancing NIEHS's research capabilities while ensuring compliance with federal regulations regarding human subjects and promoting inclusivity in research practices. Interested parties must submit their proposals by 4:00 PM EST on January 6, 2025, and can direct inquiries to Sue McKenzie at sue.mckenzie@nih.gov or Erica Kitzmiller at erica.kitzmiller@nih.gov.
    Brand Name Biological Product
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for a brand name biological product under solicitation number RFQ-NIAID-25-2251721. The procurement involves the acquisition of specific biological supplies, including various anti-human antibodies, to support the National Institute of Allergy and Infectious Diseases (NIAID) in its research efforts. These products are critical for advancing biomedical research and ensuring the availability of high-quality reagents for scientific studies. Interested vendors must submit their offers by December 22, 2024, at 10:00 AM EST, and can direct inquiries to Calvin Robinson at calvin.robinson@nih.gov.
    A--Biomedical Computing Support Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for Biomedical Computing Support Services to assist in ongoing cancer research initiatives. The procurement aims to provide comprehensive computing services that facilitate the analysis of high-dimensional biomedical data, supporting both domestic and international studies within the Division of Cancer Epidemiology and Genetics (DCEG). This opportunity is critical for enhancing cancer research capabilities, with an estimated contract value ranging from $3,000 to $147 million over a performance period of five years, beginning September 16, 2025, with a potential five-year extension. Interested offerors must submit their proposals by January 6, 2025, and can direct inquiries to Antoinette C. Robinson at antoinette.robinson@nih.gov or by phone at +1 240 276 5823.
    Access to the Florence electronic Trial Master File (eTMF) Platform- 12 Months Annual Subscription
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure a 12-month annual subscription to the Florence electronic Trial Master File (eTMF) platform. This non-competitive solicitation aims to secure a commercial item necessary for secure data storage and management for the Rare Disease Clinical Research Network (RDCRN) program, ensuring continuity and compliance with existing systems currently in use. Interested vendors must submit their quotations by 1:00 p.m. Eastern Time on December 24, 2024, referencing Solicitation Number 75N95025Q00050, and can direct inquiries to Samson Shifaraw at samson.shifaraw@nih.gov or by phone at 301-480-7153.
    65--Illumina Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI), intends to award a non-competitive contract to Illumina, Inc. for the supply of "Illumina Reagents and Consumables" essential for various sequencing and genotyping systems. This procurement is driven by the unique operational needs of NIH-owned systems, as confirmed by market research indicating that only Illumina can provide the proprietary reagents necessary to maintain research integrity and support ongoing studies. The contract performance period is set from September 3, 2025, to September 2, 2030, and interested parties may submit capability statements for review by January 6, 2025; however, this is not a solicitation for proposals. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or by phone at +1 301 496 2153.